Company profile
Tyra Biosciences, Inc. logo

Tyra Biosciences, Inc.

Pipeline3 assets

  • dabogratinibTYRA-300 / FGFR3 / Small molecule / Oncology / Skeletal Dysplasia
    Metastatic Urothelial Cancer (mUC)Non-Muscle Invasive Bladder Cancer (IR NMIBC)Achondroplasia
  • TYRA-200TYRA-200 / FGFR1/2/3 / Small molecule / Oncology
    Intrahepatic CholangiocarcinomaAdvanced Solid Tumors
  • TYRA-430TYRA-430 / FGFR4/3 / Small molecule / Oncology
    Hepatocellular Carcinoma (HCC)Advanced Solid Tumors

Latest news8 items

All news

Tyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights

- Advanced " dabogratinib 3x3 " strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH - - First LG-UTUC patient dosed with dabogratinib in SURF303; initial results expected in 2027 - - Initial Ph2 data readout from SURF302 expected in August 2026 (n>20 enrolled to date) - -

Interim Data • Phase 2SURF302 initial Ph2 data readout Sat, Aug 1, 2026

Tyra Biosciences to Participate in Upcoming Investor Conferences

CARLSBAD, Calif., May 7, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced participation at

Tyra Biosciences to Participate in Upcoming Investor Conferences

CARLSBAD, Calif., Feb. 19, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced participation

Tyra Biosciences, Inc. • Endpoint Arena